Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience (TWST) just had a massive run-up after Anthropic's protein design results put its DNA synthesis platform in the spotlight. Here's what's really driving the stock — and whether it's still a buy.

Twist has surged in recent months, fueled by growing demand for AI-enabled drug discovery and a high-profile 8-K disclosure tied to Anthropic's protein design campaign. In this deep dive, we break down Twist's silicon-based DNA synthesis platform, how it differs from traditional synthesis methods, and why manufacturing costs have fallen sharply over the past three years.

We cover the two core segments — DNA synthesis and protein solutions versus next-gen sequencing (NGS) — and which one is growing faster. We unpack customer trends across therapeutics, diagnostics, academic/government, and industrial markets, plus the rationale behind spinning off the Atlas Data Storage business. From there, we walk through Twist's fiscal 2026 guidance, free cash flow trajectory, and the dilution risk created by its $200 million and $300 million at-the-market equity offerings. Finally, we run two reverse DCF scenarios to stress-test what the market may be pricing in today, and explain why the valuation still looks rich despite the growth story.

Is TWST a buy after this run, or still just a watch-list name?

TIMESTAMPS0:00 - Why Twist Bioscience Is Back on Our Radar1:14 - How Twist's Silicon DNA Synthesis Platform Works2:36 - Cost, Waste, and Turnaround Time Improvements3:44 - Segment Breakdown: DNA Synthesis vs. NGS5:00 - Where Growth Is Coming From: Customer Industries6:35 - The Atlas Data Storage Spin-Off Explained7:14 - AI Drug Discovery: Twist's Role in the Pipeline7:50 - The Anthropic 8-K and August's Stock Spike9:20 - FY2026 Guidance, Cash Burn, and Dilution Risk11:15 - Two Reverse DCF Scenarios: What's Priced In?13:14 - Final Take: Buy, Pass, or Watch List?

—

If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com

All our socials: https://linktr.ee/chipstockinvestor

If you're getting value from the show, follow so you don't miss the next one.

—

Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction.

Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI doesn't own shares of Twist Bioscience.